← Back to Search

Cholinergic Blocker for Cognitive Impairment

Phase < 1

Recruiting

Research Sponsored by Vanderbilt University Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

age ≥ 55

Be older than 18 years old

Must not have

primary neurological disorder (such as stroke, epilepsy, etc.)

medical contraindications to the drug challenge

Timeline

Screening 3 weeks

Treatment Varies

Follow Up after administration of second drug challenge, approximately 72 hours

Summary

This trial will use a medicine that blocks a chemical called "acetylcholine" to study how it affects attention in people with Sickle Cell Disease. They think that people with SCD have to work harder to pay attention, and disrupting this process with the medicine will make it harder to pay attention.

Who is the study for?

This trial is for non-smoking adults aged 55 or older who have mild cognitive issues but are generally in good health. They should score above 25 on the MoCA test, indicating only slight memory concerns, and have a GDS rating below 3, showing minimal daily life impact.

What is being tested?

The study tests how an anticholinergic drug called Mecamylamine affects attention in aging individuals with slight cognitive decline. Participants will be compared to those taking a placebo while their brain activity and attention performance are monitored using EEG and specific tests.

What are the potential side effects?

Mecamylamine may cause side effects like dizziness, nausea, dry mouth, constipation, blurred vision or confusion. These symptoms result from its action on the nervous system but vary among individuals.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 55 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a primary neurological disorder like stroke or epilepsy.

Select...

I cannot take certain medications due to health risks.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ after administration of second drug challenge, approximately 72 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~after administration of second drug challenge, approximately 72 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and after administration of second drug challenge, approximately 72 hours for reporting.